Articles

O.2 AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers

BJH - volume 11, issue Abstract Book BHS, february 2020

N. Vandewalle , P. Vlummens MD, N. De Beule , S. Faict , I. Oudaert , K. Maes , E. De Bruyne , E. Menu , K. Vanderkerken PhD, K. De Veirman

Read more

O5 Inhibition of multiple myeloma exosomes prevents bone loss and reduces tumor growth.

BJH - 2018, issue Abstract Book BHS, february 2018

S. Faict , K. De Veirman , K. Maes , E. De Bruyne , H. Schots , R. Heusschen PhD, J. Caers MD, PhD, K. Vanderkerken PhD, E. Menu

Read more

PP01 Mucosal- associated invariant T cells deficiency in multiple myeloma can be overcome by PD-1 inhibition

BJH - volume 8, issue Abstract Book BHS, february 2017

M. Favreau , K. Venken , S. Faict , K. Maes , K. De Veirman , E. De Bruyne , X. Leleu , D. Elewaut , K. Vanderkerken PhD, E. Menu

Read more

P08 Immunotherapy in Multiple Myeloma using alfa-galactosylceramide loaded sEVs from dendritic cells to stimulate NKT activity

BJH - volume 8, issue Abstract Book BHS, february 2017

S. Faict , M. Favreau , E.D.B. E. , K. De Veirman , K. Maes , K. Vanderkerken PhD, R. Schots MD, PhD, E. Menu

Read more

P1.08 Long-term Survival and Quality of Life Analysis after Autologous Stem Cell Transplantation for Lymphoma

BJH - volume 7, issue Abstract Book BHS, january 2016

S. Faict , A. De Becker MD, K. Fostier MD, F. Trullemans , R. Schots MD, PhD

Read more